Some issues with composite endpoints in clinical trials
- 18 November 2005
- journal article
- review article
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 19 (6) , 609-619
Abstract
This article discusses some important issues that may arise in the current usage of composite endpoints as primary endpoints for demonstrating the efficacy of new drugs in clinical trials. The discussion focuses on time‐to‐event composite endpoints. Issues discussed include validity of a composite endpoint, the often lack of follow‐up of patients beyond first event, the analysis of a composite endpoint, its sub‐composite and individual component endpoints and their interpretation. Actual published examples in the literature are used to illustrate some of these problems. It is recommended that a clinical trial using a composite endpoint as the primary endpoint should be designed to include patient follow‐up beyond the first event if possible. For data collected from such trials, basic formats for tabular presentation of trial data and for results of analysis of the composite endpoint, its sub‐composite and individual component endpoints are proposed for transparency and ease of interpretation.Keywords
This publication has 51 references indexed in Scilit:
- A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic RelapseJournal of Clinical Psychopharmacology, 2003
- Mirtazapine Orally Disintegrating Tablet Versus Sertraline: A Prospective Onset of Action StudyJournal of Clinical Psychopharmacology, 2003
- Unmet Clinical Needs in Bipolar DisorderJournal of Clinical Psychopharmacology, 2003
- Combined endpoints: can we use them?Statistics in Medicine, 2002
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Raynaud's phenomenon and scleroderma dysregulated neuroendothelial control of vascular toneArthritis & Rheumatism, 1995
- The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trialsArthritis & Rheumatism, 1993
- Multiple testing in clinical trialsStatistics in Medicine, 1991